
Trend Report: Q3 2021

Purpose: This report provides up-to-date information regarding the status of NPS benzodiazepine prevalence and positivity within the United States.

Overview: Novel psychoactive substances (NPS), including NPS benzodiazepines, continue to pose great challenges for forensic scientists, clinicians, and public health and safety personnel. NPS benzodiazepines have been implicated in an increasing number of adverse health events, marked by emergency room admissions and death investigations, especially when ingested in combination with opioids. Maintaining a current scope of analysis can be challenging, requiring comprehensive analytical methodologies and reference materials for identification(s).


Objective: Our laboratory utilizes novel approaches for the analysis of drugs in biological samples and seized materials using comprehensive non-targeted data acquisition by gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). The scope of analysis contains more than 900 drugs, including a vast majority of NPS and their metabolites. This approach allows for real-time identification of new benzodiazepines and further data analysis of important trends. This project was conducted in collaboration with the toxicology and criminalistics laboratories of NMS Labs. Forensic case types linked to these results include illicit drug investigations, medicolegal death investigations, and/or driving under the influence of drugs (DUID) investigations. The results in this report represent the total number of NPS identifications at CFSRE during this quarter, including those from sample-mining, data-mining, and/or esoteric testing.



NPS BENZODIAZEPINES IDENTIFIED

Pyrazolam	1		•	Foxicology	Seized	l Drug
Estazolam	1					
Diclazepam	1					
Metizolam	2					
Bromazepam	3					
Adinazolam	4					
Deschloroetizolam	1 0					
Desalkylflurazepam	1 0					
Flubromazepam	17					
Bromazolam	33					
Flubromazolam		71				
Clonazolam			121			
Flualprazolam			126			
Etizolam						

SELECT POSITIVITY SINCE Q1 2019



Acknowledgements: This report was prepared by Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda LA. Mohr, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. NPS Discovery would like to acknowledge scientists at CFSRE and NMS Labs for their involvements and contributions. For more information about our programs and reports, please contact NPS Discovery at <u>mpdiscovery/dicfsre.org</u> or visit our website at <u>www.npsdiscovery.org</u>.

Funding: NPS Discovery at the CFSRE is supported in part by the National Institute of Justice Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BR-0007, "Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive

Substances (NPS)"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.

